Skip to main content

Chemotherapy’s effectiveness may vary with time of day, suggests WVU research

Full moon obscured by clouds.

New research led by William Walker—a postdoctoral fellow with the WVU School of Medicine—suggests that chemotherapy could better target brain tumors in mouse models when it was administered at night instead of during the day. That’s because the blood-brain barrier was more likely to allow the chemotherapy to pass through it at night. The findings highlight the importance of this area of research in humans, and one day, they could help to improve outcomes in patients with brain tumors. (WVU Photo)

Download full-size

The blood-brain barrier keeps foreign substances from entering the brain. That’s good when it comes to toxins and germs, but it makes treating tumors in the brain trickier. By shielding the brain from things that would harm it, the blood-brain barrier also blocks the chemotherapy that would help it.

William Walker—a researcher with the West Virginia University School of Medicine—is investigating whether the blood-brain barrier is more likely to admit chemotherapy drugs at different times of day. 

His study—funded by the National Institutes of Health—shows that the blood-brain barrier is dynamic rather than static and suggests that properly timed chemotherapy treatments could better reach the tumors they’re targeting. 

“We are not the first ones to show that chrono-chemotherapy is beneficial, but we’re the first to show that it’s beneficial in the treatment of brain metastasis,” said Walker, a postdoctoral fellow in the Department of Neuroscience

His findings appeared in "Frontiers in Oncology."

Walker and his colleagues delivered chemotherapy into mice that had breast cancer, which had traveled to the brain. 

Some of the mice received the treatments in daylight conditions, when mice—being nocturnal—are typically at rest. The other animals received them in the dark, a setting that more closely resembles the mice’s active period.  

The researchers found that the chemotherapy they administered during the dark phase killed more brain tumor cells than the ones given in the light phase.

Dark-phase chemotherapy treatments also did a better job of delaying neurological symptoms, like strange walking patterns and loss of muscle control. 

They also increased the median survival rate by about 20%.

“In all our projects, we try to ask, ‘If we see an effect molecularly, does that translate? Is there a functional relevance to it?’” Walker said. “To an extent, it might be pointless if we increase the amount of chemotherapy within the brain tumor at a certain time, but we don’t see any functional difference, we don’t improve survival, or we don’t improve changes in neurological deficit. So, these results were great to see.”

Questions remain. Does the human blood-brain barrier fluctuate, too? If it does, is it more receptive to chemotherapy in the day or at night? Do the fluctuations reflect the fact that humans are diurnal creatures (more active during the day), or are they an effect of light exposure itself?

“Those are the questions William Walker will be looking into when he leaves this lab and starts his own,” said Randy Nelson, chair of the Department of Neuroscience, director of the WVU Center for Foundational Neuroscience Research and Education and Walker’s mentor. 

Typically, people on chemotherapy receive their treatments in the daytime—during regular business hours—but “if it’s the case that people are more like flies, and the brain blood-brain barrier opens up at night, then that might be the best time to give chemo,” Nelson said.  

“Chrono-chemotherapy has been shown to be beneficial for years—in terms of peripheral cancer—but for some reason, that basic science is not being translated to clinical practice,” Walker said. “I think that’s an important step. That’s my goal in starting my own lab: to try to raise awareness so that we can actually translate some of the basic science that we see into clinical practice to improve patient outcomes.”

Research reported in this publication was supported by the National Institute on General Medical Sciences of the National Institutes of Health, under Award Number 5U54GM104942-03. The researchers were supported by grants from NIGMS (Award Number P20GM121322 to Paul Lockman), the National Cancer Institute (Award Number 5R01CA194924 to A. Courtney DeVries and Award Number F99CA253768 to Samuel Sprowls), the National Institute of Neurological Disorders and Stroke (Award Number 5R01NS092388 to Nelson and DeVries) and the WVU Mylan Chair Endowment Fund (to Lockman). The content is solely the responsibility of the authors and does not necessarily represent the official views of NIGMS, NINDS, NCI or NIH


Title: Circadian influences on chemotherapy efficacy in a mouse model of brain metastases of breast cancer



Editor’s note: The use of animals in this project was evaluated by WVU’s institutional animal care and use ethics committee. West Virginia University is voluntarily accredited by AAALAC, a national peer organization that establishes a global benchmark for animal well-being in science.



CONTACT: Cassie Thomas
Director, Communications and Marketing
WVU School of Medicine

Call 1-855-WVU-NEWS for the latest West Virginia University news and information from WVUToday.

Follow @WVUToday on Twitter.